Evidence map›Paper›PMID 20441547›Full record

ReviewFuture microbiology2010

Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity.

Lee M Wetzler

Open access · greenAbstract readReview
In one paragraph

Review in Future microbiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Deciphering the Interactome ofFrontiers in microbiology · 2018
    Article
  8. Frontiers in immunology · 2017
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Targeting TLR2 for vaccine development.Journal of immunology research · 2014
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Lee M WetzlerBoston University School of Medicine, Boston, MA, USA. lwetzler@bu.edu

Funding

Neisserial Porins and Antigen Presenting CellsR01AI040944 · NIAID · BOSTON MEDICAL CENTER · PI WETZLER, LEE MARK · 1997 to 2019
$9.3M
NIAID NIH HHS AI040944NIAID NIH HHS R01 AI040944
6 · The paper itself

Abstract

Neisseria meningitidis is a Gram-negative pathogenic bacteria responsible for bacterial meningitis and septicemia. Porins are the most represented outer membrane proteins in the pathogenic Neisseria species, functioning as pores for the exchange of ions, and are characterized by a trimeric beta-barrel structure. Neisserial porins have been shown to act as adjuvants in the immune response via activation of B cells and other antigen-presenting cells. Their effect on the immune response is mediated by upregulation of the costimulatory molecule B7-2 (CD86) on the surface of antigen-presenting cells, an effect that is dependent on Toll-like receptor (TLR)2 and MyD88, through a cascade of signal transduction events mediated by direct binding of the porin to the TLR2-TLR1 heterodimer. This article summarizes work carried out investigating the mechanisms of the immune stimulating capacity of the neisserial porins (specifically meningococcal PorB), emphasizing cellular events involved in antigen-presenting cell activation and induction of expression of cell surface molecules involved in the immune response.

Indexed as

Adjuvants, ImmunologicAntigen-Presenting CellsMeningococcal VaccinesNeisseria meningitidisPorinsReceptors, ImmunologicAdjuvants, ImmunologicMeningococcal Vaccinesporin protein, NeisseriaPorinsReceptors, Immunologic

Identifiers

PMID20441547
PMCPMC2907731
OpenAlexW2090236981

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.